Artwork

Konten disediakan oleh Talking About Tumors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Talking About Tumors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

04_08 Metastatic Renal Cell Carcinoma

24:16
 
Bagikan
 

Manage episode 432118872 series 3335024
Konten disediakan oleh Talking About Tumors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Talking About Tumors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
  2. Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
  3. Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
  4. Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
  5. Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
  6. Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
  7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
  8. Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
  9. Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
  10. Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
  11. Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

48 episode

Artwork
iconBagikan
 
Manage episode 432118872 series 3335024
Konten disediakan oleh Talking About Tumors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Talking About Tumors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
  2. Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
  3. Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
  4. Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
  5. Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
  6. Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
  7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
  8. Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
  9. Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
  10. Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
  11. Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

48 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat